3D-printed prednisolone phosphate suppositories with tunable dose and rapid release for the treatment of inflammatory bowel disease

Int J Pharm. 2024 Jan 5:649:123639. doi: 10.1016/j.ijpharm.2023.123639. Epub 2023 Nov 30.

Abstract

Established medicines are often not tailored to the needs of the pediatric population, causing difficulties with administration or dosing. Three-dimensional (3D) printing technology allows novel approaches for compounding of personalized medicine, as is exemplified in this study for the automated compounding of rectal preparations for children. We investigated the material requirements to print prednisolone phosphate-loaded suppositories with tunable dose and rapid drug release for the treatment of inflammatory bowel diseases. Three formulations containing 4 % w/w prednisolone sodium phosphate (PSP) and different amounts of hydroxypropyl cellulose (HPC) and mannitol as excipients were printed as suppositories with a fused deposition modeling (FDM) 3D-printer. Dissolution studies showed that the PSP release rate was increased when higher weight fractions of mannitol were added as a pore former, with 90 % drug release within 30 min for mannitol 48 % w/w. We further printed suppositories with 48 % mannitol with different infill densities and dimensions to tune the dose. Our findings demonstrated that 3D-printed suppositories with PSP doses ranging from 6 to 30 mg could be compounded without notably affecting the dissolution kinetics, ensuring equivalent therapeutic efficacies for different doses.

Keywords: Fused deposition modeling; Hot-melt extrusion; Infill density; Personalized medicine; Rectal administration.

MeSH terms

  • Child
  • Drug Liberation
  • Humans
  • Inflammatory Bowel Diseases*
  • Mannitol
  • Printing, Three-Dimensional
  • Suppositories
  • Tablets
  • Technology, Pharmaceutical* / methods

Substances

  • prednisolone phosphate
  • Tablets
  • Suppositories
  • Mannitol